Johns Hopkins has $65M to spend on taking their drugs right up to human studies
Researchers at Johns Hopkins University now have a new way to take a promising therapy to the threshold of Phase I, burnishing the value of what they have for the spinouts and biopharma groups that will take a select few therapies to the clinic.
Deerfield Management is funding the program with $65 million to start. But that money, of course, comes with strings attached.
The new in-house incubator is called Bluefield Innovations, and its primary goal is to advance Johns Hopkins research that shows strong commercial promise. The program will take the university’s research through pre-clinical development all the way to IND.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.